$CERT

MindWalk Holdings Corp. (HYFT) reported a 46% revenue increase to C$15.6M, with improved margins and narrowed losses. The company focuses on AI-enabled drug discovery, emphasizing its data and systems of record. Comparatively, Veeva Systems (VEEV) rose after strong earnings, while Certara (CERT) and Recursion (RXRX) fell due to missed expectations, highlighting market preference for proprietary data.

Cerrado Gold reported Q2 2026 results: 15,415 GEO produced at AISC of $1,933/oz, $28.2M adjusted EBITDA, and $25.3M cash. Annual guidance maintained at 50,000-60,000 GEO. MDN mine saw production increases, while Lagoa Salgada and Mont Sorcier projects advanced. Management to host call August 19.

Certara, Inc. reported Q2 2026 updates on its shift to specialist, scientist-led sales and a divestiture of its regulatory and medical writing business. Software revenue is 53% of total, up from 40% two years ago. Full-year revenue guidance is 0% to 4%, with adjusted EBITDA margin guided at 29% to 31%. Net loss from continuing operations was $6.1M. A new $50M share repurchase was authorized.

Certara (CERT) reported Q2 2026 revenue of $93.3 million, up 1% YoY, with software revenue $48.8 million (+4%) and services $44.5 million (-3%). Total bookings were $98.3 million (+1%). Adjusted EBITDA was $26.2 million (28.1% margin). 2026 guidance: revenue $367-$382 million and adjusted EPS $0.31-$0.36. The company completed a divestiture and is integrating AI, and announced NVIDIA partnership.

Certara, Inc. (CERT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Certara Reports Second Quarter 2026 Financial Results A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guid

Certara, Inc. (CERT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 4, 2026, Certara, Inc. (the “Company”) announced the departure of Leif E. Pedersen from his role as the Company’

Cerrado Gold said it will extend the completion timing of the Mont Sorcier bankable feasibility study to incorporate optimization work. The company plans mine-plan changes to reduce strip ratio, review tailings dam and CAPEX/OPEX amid inflation, and assess a 65% vs 67% iron concentrate trade-off. It expects ESIA filing in Q2 2027 and permits around year-end 2028.

Certara said it is integrating Nvidia’s BioNeMo Agent Toolkit into its AI drug development platform, adding agentic frameworks to support tasks across dosing optimization, clinical-data analysis, ADMET evaluation and regulatory evidence. Silo Pharma’s subsidiary QwikAgents joined Nvidia’s Developer Program to expand its autonomous AI agent platform. NVDA shares were up; Certara and Silo were down at publication.

Certara (Nasdaq: CERT) said it is partnering with NVIDIA to integrate NVIDIA’s BioNeMo Agent Toolkit into Certara’s open AI platform. The toolkit is positioned as an agentic framework that can use Certara’s biosimulation models, datasets, and regulatory expertise to generate life-sciences insights across drug development. The company did not provide financial figures.

Certara, Inc. (CERT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001827090 0001827090 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor